| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
| | IP | CI | | Ebvallo | | PR | PR | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G |  |
L | | IP | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10 % | | Concentrate for infusion: Bevacizumabum 100mg / 4ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | IP | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10 % | | Concentrate for infusion: Bevacizumabum 400mg / 16ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | IP | | PP | Herceptin subkutan 600mg/5ml | | 1484.04 | 1630.40 | 10 % | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma (Schweiz) AG | A / SL | FB | | G |  |
L | | IP | | | Ogivri 150 mg | | 456.84 | 513.25 | 10 % | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G |  |
| | IP | CI | | Bilaxten 6 mg / ml | 5 ml | PR | PR | k.A. | | Eye drops: Bilastinum 6 mg/ml | A. Menarini GmbH | B | FB | | G |  |
| | IP | CI | | Regaine 2 % | 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 20 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | CI | | Regaine 2 % | 3 x 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 20 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | CI | | Regaine 5 % | 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | CI | | Regaine 5 % | 3 x 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | | | Mylotarg 5 mg | | PR | PR | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G |  |
|
L | | IP | | V/S | Boostrix Polio | | 24.86 | 43.45 | 10 % | | 4 Active Agents | GlaxoSmithKline AG | B / SL | FB | | G |  |
L | | IP | | V/S | Infanrix DTPa-IPV | | 20.20 | 38.40 | 10 % | | 8 Active Agents | GlaxoSmithKline AG | B / SL | FB | | G |  |
L | | IP | | V/S | Tetravac | | 20.21 | 38.40 | 10 % | | Injection suspension: 2 Active Agents | Sanofi-Aventis (Suisse) SA | B / SL | FB | | G |  |
| | IP | | V/S | Boostrix Polio | 10 | PR | PR | k.A. | | 4 Active Agents | GlaxoSmithKline AG | B | FB | | G |  |
L | | IP | | V/S | Adacel-Polio 0.5 ml | 0.5 ml | 24.00 | 42.50 | 10 % | | | Sanofi-Aventis (Suisse) SA | B / SL | FB | | G |  |
| | IP | | V/S | Adacel-Polio 0.5 ml | 0.5 ml | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Adacel-Polio 0.5 ml | 0.5 ml | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Adacel-Polio 0.5 ml | 10 x 0.5 ml | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Adacel-Polio 0.5 ml | 10 x 0.5 ml | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Adacel-Polio 0.5 ml | 10 x 5 ml | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |